2015 Full Year Results

Transatlantic Healthcare Technology GroupFocused on value creation through execution

François R Martelet, M.D.Chief Executive Officer

Mark NanovichInterim CFO

7 April 2016

This presentation is not an offer or solicitation of an offer to buy or sell securities. It is solely for use at this investor meeting and is provided for information only. This presentation does not contain all the information that is or may be material to a prospective investor (such as risk factors). By attending the presentation or by reading the presentation slides you agree to be bound as follows:

This presentation has been prepared by NetScientific plc (the “Company”), is strictly confidential and is not, and should not be construed as, a prospectus or listing particulars relating to the Company. This presentation does not constitute or form part of, and must not be construed as, an offer or invitation to subscribe for, underwrite or otherwise acquire, or a recommendation regarding, any securities of the Company, nor should it or any part of it form the basis of or be relied on in connection with (i) any contract to purchase or subscribe for any securities of the Company, or (ii) any other contract or commitment whatsoever. Nothing in this presentation shall be deemed to be binding against, or to create any obligations or commitment on the part of, any prospective investor or the Company. The contents of this presentation should not be considered to be legal, tax, investment or other advice, and any prospective investor considering the purchase of any securities of the Company should consult with its own counsel and advisers as to all legal, tax, regulatory, financial and related matters concerning an investment in such securities and as to their suitability for such prospective investor.

This presentation has been made to you solely for your information and background for discussion purposes only, and may be amended and supplemented and must not be relied upon for the purpose of entering into any transaction. This presentation and its contents are confidential and proprietary to the Company, and no part of it or its subject matter may be reproduced, redistributed, passed on, or the contents otherwise divulged, directly or indirectly, to any other person (excluding the relevant person’s professional advisers) or published in whole or in part for any purpose without the prior written consent of the Company. If this presentation has been received in error it must be returned immediately to the Company.

This presentation is not directed to or intended for distribution, or transfer, either directly or indirectly to, or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, transfer, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. In particular, neither this presentation nor any copy hereof may be sent, or taken, transmitted or distributed, directly or indirectly, in or into Australia, Canada, Japan, or the United States (including its territories and dependencies, any state of the United States and the District of Columbia) or to any resident of Australia, Canada or Japan. This presentation is only being provided to persons outside of the United States in reliance on exemptions from the US Securities Act of 1933, as amended (the “Securities Act”).

This presentation does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein or offered in connection with this presentation have not been, and will not be, registered under the Securities Act. They may not be offered, sold, transferred, distributed or delivered, directly or indirectly within, into or in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. No public offering of the securities will take place in the United States. Neither the US Securities and Exchange Commission nor any securities regulatory authority of any state or other jurisdiction of the United States has approved or disapproved of an investment in the securities or passed on the accuracy or adequacy of the contents of this presentation. Any representation to the contrary is a criminal offence in the United States.

This communication is directed at (i) persons outside the United Kingdom, or, if this presentation is intended for distribution in the United Kingdom, (ii) solely to (a) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”); (b) members or creditors of a corporate body within the meaning of article 43 of the order; (c) those persons falling within Article 49(2)(a) to (d) of the order; or (d) those persons to whom it can otherwise be distributed without contravention of Article 21 of the Financial Services and Markets Act 2000 or to whom it may otherwise lawfully be distributed (each, a “relevant person”). This presentation must not be acted or relied upon by persons other than relevant persons. Any investment or investment activity to which this communication relates is available only to (i) in the United Kingdom, relevant persons and, (ii) in any member state of the European Economic Area other than the United Kingdom, “qualified investors” within the meaning of article 2(1)(e) of the Prospectus Directive (Directive 2003/71/EC), and will be engaged in only with such persons.

This presentation contains forward-looking statements. These statements may include the words “believe”, “expect”, “anticipate”, “intend”, “plan”, “estimate”, “project”, “will”, “may”, “targeting” and similar expressions as well as statements other than statements of historical facts including, without limitation, those regarding the financial position, business strategy, plans, targets and objectives of the management of the Company for future operations (including development plans and objectives). Such forward-looking statements involve known and unknown risks, uncertainties and other important factors which may affect the Company's ability to implement and achieve the economic and monetary policies, budgetary plans, fiscal guidelines and other development benchmarks set out in such forward-looking statements and which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company’s present and future policies and plans and the environment in which the Company will operate in the future. Furthermore, certain forward-looking statements are based on assumptions or future events which may not prove to be accurate. The forward-looking statements in this presentation speak only as of the date of this presentation, and the Company expressly disclaims to the fullest extent permitted by law any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. Nothing in the foregoing is intended to or shall exclude any liability for, or remedy in respect of, fraudulent misrepresentation.

The information in this presentation has been verified by NetScientific only, and has been independently verified by any other person. No representation or warranty, express or implied, is made as to the fairness, accuracy or completeness of the presentation and the information contained herein and no reliance should be placed on it. Information in this presentation (including market data and statistical information) has been obtained from various sources (including third party sources) and the Company does not guarantee the accuracy or completeness of such information. All projections, valuations and statistical analyses are provided to assist the recipient in the evaluation of matters described herein. They may be based on subjective assessments and assumptions and may use one among alternative methodologies that produce different results and to the extent they are based on historical information, they should not be relied upon as an accurate prediction of future performance.

No representation is made as to the reasonableness of the assumptions made within or the accuracy or completeness of any modelling, scenario analysis or back-testing. The information in this presentation is not intended to predict actual results and no assurances are given with respect thereto. None of the Company, its advisers, connected persons or any other person accepts any liability whatsoever for any loss howsoever arising, directly or indirectly, from this presentation or its contents. All information, opinions and estimates contained herein are given as of the date hereof and are subject to change without notice. The financial information referenced in this presentation was derived from financial estimates and/or statements prepared in accordance with accounting principles generally accepted in the United Kingdom (“UK GAAP”).

The financial data in this presentation are solely for your information, as background for discussion purposes and may not be relied upon for the purpose of entering into any transaction. The unaudited pro forma financial information set out in this presentation is based on certain important assumptions and adjustments and does not purport to represent what our results of operations actually will be in any future periods.

This presentation does not disclose all the risks and other significant issues related to an investment in any securities of the Company / any transactions referred to herein. In making any investment decision, prospective investors must rely on their own examination of the Company and the terms of any transaction, including the merits and risks involved.

Disclaimer

NetScientific Group PLC New Group CEO Francois R. Martelet, M.D – 20 years industry experience Realign focus on healthcare Digital Health, Diagnostics & Therapeutics Portfolio rationalisation Divested non-core investments with significant savings Reorganisation High calibre CEO’s recruited for Wanda, ProAxsis, Vortex, Glycotest Fundraising £18.2m fundraising Finance £23.2m available cash resource, divestment of non-core assets

Portfolio Vortex Critical patent granted. Manufacturing partners selected to support placements Wanda Significant team scale up, new software releases ProAxsis Commercial launch of first lab-based immunoassay in Q3. New data released Glycotest Continued development of HCC panel and added board member Glucosense Development of the alpha prototype PDS Biotechnology Positive preliminary data showing strong T-cell responses in pre-cervical cancer

Full year results: highlights

2015 was a turnaround year for the Group3

NetScientific Group PLC Additional Board member Professor Stephen Smith – distinguished clinician, ex-CEO and entrepreneur New CFO Ian Postlethwaite to join, ex-FD at Allergy Therapeutics. Lean PLC team in London

Portfolio Vortex VTX-1 instrument to be shipped to leading US researches in Q2 for Beta testing Wanda Two new commercial agreements in Q1 – HRS & Dignity Health (Oncology) ProAxsis World class Scientific Advisory Board appointed Glycotest Medical Advisory board appointed PDS Biotechnology Signed a Cooperative Research and Development Agreement with the US National

Cancer Institute to co-develop novel cancer immunotherapies through Phase II clinical trials

Post period-end highlights

4

Vijay Barathan, MDChief Investment Officer

Ian PostlethwaiteCFO (start date TBD)

Francois Martelet, MDCEO

Healthcare Investment Banker Peel Hunt and Piper JaffrayMedical Doctor NHS

Ernest SchneiderCommercial-Legal Director

Partner Reynolds Porter Chamberlain and Mishcon De ReyaFounder Schneider Page

FD Allergy TherapeuticsSenior finance positions as AFS, Ericsson, Philips Electronics

CEO TopotargetCEO Avax TechnologiesSenior positions at Merck & CO, Novartis, Schering-Plough and Eli Lilly

PLC Group management team strong and focused

CEO, Chairman of GSK Chairman NHS LondonRector Imperial CollegeFellow Royal Society & Academy of Medical Sciences

President of MedtronicPresident of LederlePresident of BMS Europe

Jonathan PaisnerNED

Barry WilsonNED

Sir Richard Sykes Chairman

Founder LMN CapitalLawyer Mathias Gentle Page HassanBoard Shore Capital

Prof. Stephen SmithNED

CEO Imperial College TrustDean Medicine, Dentistry and health science University of MelbourneFounder Metris Therapeutics and GNI Group

PLC Boardsignificant experience to leverage and build value

Strong and focused management team and Board

5

San Francisco & Philadelphia offices /36 Employees

USA UK

Digital Health Diagnostics Therapeutics Digital Health Diagnostics London HQ/8 employees UK/12 Employees

Listing AIM (NSCI)

Funds raised c.£48m

No. of Shares 51,075,695

Share price (6/4/2016) 72.5p

Market Cap (6/4/2016) £37m

Shareholders (>3%) 45.1% Woodford Investment Management18.1% Invesco Asset Management 9.2% JO Hambro20.4% Azima Family Trusts

NetScientific’s mission is to change the paradigm of care in chronic diseases

6

Commercial stage Development stage

Gene Walther Steve Curd David Ribeiro Larry Cohen

Leadership Deputy Director Gates FoundationChairman GenturaDxPresident diagnostics Novartis and Chiron

CIO United HealthCOO WebMDCOO NANTHEALTHCEO CareinSync

Business Manager EU PharmaxisUnit Director PfizerGlobal product Director Solvay

CEO Exalenz BioscienceCEO SenGenixCEO IVD SolutionsPresident ITCVP J&J

Product Cancer diagnostic instrument for isolation and collection of circulating tumour cells

Advanced chronic disease management platform based on machine learning

Respiratory diagnostic test for monitoring patients with Cystic Fibrosis and COPD

Blood tests for liver diseases

Business modelInstrument and consumable cartridge sales

Clinical research labs

Software as a service

Providers/payors/pharma

Test kits and point of care device sales

Pharma/clinics/home

Lab sales

CLIA labs

Grant funding £1.6m £7.7m £1.0m £5.9m

NetScientificInvestment as at 31 Dec 15

£5.6m (£6.9m as at 31 Mar 16) £5.1m (£6.0m as at 31 Mar 16) £0.1m (£0.6m as at 31 Mar 16) £1.2m (£1.5m as at 31 Mar 16)

NetScientific shareholding 95% 71.3% 56.5% 87.5%

7

Game changing portfolio with new management teams

2016 / 2017 – building value in PLC

Exit

Priority Portfolio

Growth CapitalPipeline

Capital returned to shareholders

Series A financings

IPO / M&A

H2 20162017

Global institutions, technology incubators, deep healthcare network

8

Financials – results for the year

9

2015£’000

2014£’000

Loss from Continuing operations 11,229 6,179

Loss from Discontinued operations 1,517 948

Loss for the year 12,746 7,127

Loss from Continuing operationsR&D 7,256 3,098

G&A 3,182 2,495

Other costs 1,077 717

Tax credit/Income (286) (131)

11,229 6,179

Financials – balance sheet & cash flow

10

2015£’000

2014£’000

Balance Sheet - highlightsCash at bank ** 23,239 16,867

Investment in PDS 1,757 1,757

Net assets 24,583 18,696

** Balance as at 31 March 2016 - £19.5m

Cash flowNet proceeds Capital raising 17,147 -

Funds used in operations (10,714) (6,631)

Other (273) (2,189)

Increase/(decrease) in cash 6,160 (8,820)

PLC has completed its turnaround Re-structured, re-focused, portfolio rationalised – divested non-core assets Highly experienced lean management team in London in place Positive momentum in lead portfolio companies – talented CEOs in place to lead the next phase of

value creation with game-changing assets

PLC is working on building shareholder value Renewed IR/PR effort to broaden the shareholder base in UK and US Goal is to deliver value enhancing news flow in 2016 : commercial traction and external valuation

from portfolio company financings Actively managing current portfolio to value realization including Series A for Wanda, ProAxsis and

Glycotest

Summary and outlook

11

Vortex & Wanda

Executive summary• Research tools and diagnostics company developing a novel liquid biopsy

technology that could revolutionize cancer research, drug development, diagnosis, monitoring and treatment

• $22B market opportunity*

• Patented microfluidic technology yields intact circulating tumor cells (CTCs)

• Outperforms competitors in key fields – purity (specificity) and collection efficiency (sensitivity)

• Significant growth opportunities as the product pipeline expands from research to also providing clinical information from CTCs

* J.P. Morgan Liquid Biopsy Report – May 27, 2015 14

The Company

• Formed in 2012 based on research done by PECASE (Presidential Early Career Award for Science and Engineering) winner Dino Di Carlo at UCLA

• Late stage development phase – placing Beta & KOL units in 2016

• Exciting R&D presents near-term growth opportunities in the rapidly growing liquid biopsy market

• Placement of VTX-1 with key opinion leaders (KOLs), onboarding of sales and marketing staff and critical publications will drive demand

• New CEO appointed – Gene Walther experienced leader in diagnostics and medical devices

15

Leadership team

Elodie Sollier-Christen, Ph.D

CSO & VP R&D

MichaelKocherspergerCTO & VP Engineering

• President Chiron/Novartis Diagnostics

• CEO Gentura Dx• Deputy Director Bill & Melinda

Gates Foundation

• Ph.D Microfluidics• UCLA, Stanford• Expertise in microdevices

for blood sample prep.

• Director Orchid Biosciences• VP New Brunswick Scientific • VP BioNanomatrix• J&J

Gene Walther, MBA

CEO

Steven Crouse, MBA

CCO

• SVP FreeSlate• Director BioRad• Invitrogen• Biosource

Bob Englert, MBAVP Manufacturing

• Abbott Laboratories• Biomedtrics• Pelikan Technologies

16

Circulating tumor cells (CTCs) detach from a solid tumor and enter the blood stream playing a crucial role in cancer metastasis.

Challenges to CTC isolation

• Extremely rare: 1-100 CTCs per mL of blood

• Other cells: millions of WBCs and billions of RBCs per mL of blood

Vortex liquid biopsy captures circulating tumor cells…

17

Technology

Cells enter the device and are ‘focused’ into an equilibrium position

CTCs selectively enter the ‘Vortex’

Red and white blood cells flow out of the system

Intact CTCs released for further analysis in cytopathology,propagation, drug development, treatment selection/effectivity and next generation sequencing

• 12 patents, 3 granted, 6 licensed – starting internal IP

• 10 publications

18

VTX-1 Workflow

19

CTC Analysis (Viability, Purity, Automation)

• Cancer Research

• Patient Prognosis

• Personalized Therapy

• Drug Development & Testing

CTC Enumeration (Efficiency, Cost)

• Early Stage Diagnosis

• Patient Prognosis

• Treatment Outcome Monitoring

• Residual Disease* JP Morgan liquid biopsy report – May 27, 2015

CTC potential$22B market by 2020*

Cancer Research Personalized Medicine

Drug Development Cancer Diagnostic Cancer Monitoring

20

Opportunities – focused growth

CTCsctDNA

• Enabling key applications beyond cancer research

• Combining CTC isolation with new platforms

21

Cell affinity Filtration Active forces Inertial microfluidics

Marker independent

Most cancers

No pre-processing Depends

High-purity

Rapid processing Depends

Large input volume

Live cells

Flexible collection

Other body fluids

Companies J&J CellSearch,

Biocept,Cynvenio

Rarecell, Creatv Microtech

Angle,Apocell

Clearbridge, J&J/MGH

VTX-1 is potentially best in class technology…

22

Product overview

Name Vortex VTX-1 Liquid Biopsy System

Key Dates Soft Research Market Launch, April 2016Global Commercial Launch, Q1 2017

Instrument price ASP ~ $120,000 (TBC – pricing study)

Cartridge priceTarget GP %

ASP ~ $200 (TBC – pricing study)80+%

Key Partnerships

Accel to manufacture first 5 unitsGener8 selected as contract manufacturer for VTX-1 Symbient/Z-Microsystems for cartridge

Sales Strategy Direct to user (US), academic and industryInternationally (TBD) Cartridge bottom

Gasket material

Cartridge top with deep pocket

23

Commercial Milestones

2016 2017

Q1 Q2 Q3 Q4 Q1 Q2-4

Beta placements

AACR soft launch(Research market)

KOL placements

Full commercial launch

VTX-1 contract manufacturing

Cartridge contract manufacturing

Gener8

Z Microsystems

24

Executive summary

26

Chronic condition management company that aims to reduce hospitalization costs and improve patient quality of life

New CEO hired – Steve Curd proven digital health leader

$2B initial market opportunity – exponential growth*

Patented systems developed from over 12 years of clinical research at UCLA

Commercialisation underway – 2 new customers

*Investec analyst note

Leadership Team

27

SteveCurd, MBA

CEO

MarkHeinemeyer

CCO

FoadDabiri, Ph.D

CTO

Opportunity: healthcare's trillion $ problem

28

75% of the $3.0 trillion fighting chronic conditions

50% of patients treated for heart failureare re-hospitalized within 6 months

These readmissions cost theU.S. $17 billion/year

Even worse are the human costs. Patients suffering from chronic conditions experience disabling and long-term symptoms. In addition, 7 out of every 10 deaths are a result of these costly and often preventable diseases

Value proposition

29

WANDA aims to reduce this trillion $ burden by preventing hospital admissions and reducing readmissions through a bifurcated consumer and clinical strategy

Predict

CliniciansIntervene based onactionable insights

Reducereadmission

s

Inform & Guide

Reduceadmissions

Engage

Collect data

How we are different

30

Science and research driven• Technology developed from multiple clinical trials - including 1,500 patient clinical

study• Strong IP position

True predictive analytics and machine learning

Contextual data and real-time vitals

Mobile application• Not typically used by analytics or RMS companies

Patient engagement/adherence driven by the worlds largest, most validated personality database

Revenue generating

Uniquely positioned against competition

31

Analytics RMS

Engagement

MD RevolutionAccoladeTacticoMDLive

SoteraVitalConnect

HealthCatalystMedeAnalyticsCloud-MedXSyTrue

SentrianViterion

VivifyHealthZypherLIFEOmada

Business model – B2B

Enables ubiquitous care

Engage, monitor and prioritize patients with chronic conditions, to improve efficiency& workflow

Reduce hospitalizations and cost

Delegate more care to the patient

Provide clinicians with actionable insight

Patient Engagement – Mobile App

32

Home Health system

Large hospital groups

Payers

Skilled nursing facilities

Target customers:

Sales update - HRS

33

HRSOne call hi-tech nursing & rehab

Health Resource Solutions, Chicago-based home health agency

Works with more than 1,000 patients/month, will be using an app to keep tabs on its patients with CHF and COPD

HRS is among a number of home health agencies turning to digital health to improve the post-discharge process for patients with chronic conditions

$60/month/patient with an upfront $225/patient kit

In production now; estimated ramp up to > 50 patients/month

Business model: growth strategy

34

Targeting customers earlier in the value curve to have more impact

Access pay-for-performance market through growth into population health

Stage A(early onset)

Stage B Stage C

Currently engage patients after they have experienced a hospitalization

D2C

CHF PopulationMax impact

Stage D(late stage)

Econ

omic

impa

ct

Milestones

35

2016 Goals Drivers

Participants registered 4,000 • B2B sales ex. HRS• D2C early platform adopters

Revenue $800K • Oncoverse and HRS

Commercial agreements 4• Large hospital groups• Payers• Home health systems• Skilled nursing facilities

Wanda Health Management Releases 4 • In-house R&D• Market research

Predictive Modules 3 • In-house R&D

Oncoverse Releases 3 • In-house R&D

Android & Apple iOS Mobile Releases 4 • In-house R&D

NetScientific.net